
  
    
      
        Background_NNP
        Despite_IN tremendous_JJ progress_NN in_IN developing_VBG
        anti-retroviral_JJ drugs_NNS to_TO combat_VB HIV_NNP ,_, there_EX remains_VBZ a_DT need_NN
        for_IN an_DT effective_JJ HIV_NNP vaccine_NN ._. This_DT need_VBP is_VBZ particularly_RB
        pressing_VBG in_IN third_JJ world_NN countries_NNS ,_, where_WRB demographics_NNS and_CC
        economics_NNS make_VBP drug_NN therapy_NN difficult_JJ to_TO deliver_VB ._. Although_IN
        HIV_NNP infection_NN elicits_NNS neutralizing_VBG antibodies_NNS and_CC a_DT
        cellular_JJ immune_JJ response_NN against_IN the_DT virus_NN [_NN reviewed_VBN in_IN [_NN 1_CD
        ]_NN &_CC [_NN 2_CD ]_NN ]_NN and_CC there_EX exist_VB "_'' exposed_VBN uninfected_JJ "_'' (_( EU_NNP )_)
        individuals_NNS that_WDT appear_VBP to_TO have_VB acquired_VBN resistance_NN to_TO
        infection_NN by_IN HIV_NNP [_NN 3_CD 4_CD ]_NN ,_, the_DT hallmark_NN of_IN HIV_NNP infection_NN is_VBZ
        the_DT almost_RB universal_JJ inability_NN of_IN humans_NNS to_TO mount_VB an_DT immune_JJ
        response_NN that_WDT can_MD prevent_VB the_DT eventual_JJ development_NN of_IN
        AIDS_NNP ._.
        An_DT effective_JJ vaccine_NN will_MD require_VB not_RB only_RB the_DT design_NN of_IN
        effective_JJ immunogens_NNS ,_, but_CC also_RB the_DT design_NN of_IN optimized_JJ
        protocols_NNS of_IN immunogen_NN delivery_NN ._. As_IN a_DT live_VB ,_, attenuated_JJ
        vaccine_NN for_IN HIV_NNP is_VBZ considered_VBN difficult_JJ to_TO test_VB and_CC
        dangerous_JJ to_TO implement_VB [_NN 1_CD 2_CD 5_CD 6_CD 7_CD 8_CD 9_CD ]_NN ,_, various_JJ
        alternatives_NNS to_TO HIV_NNP could_MD be_VB considered_VBN as_RB potential_JJ "_'' live_VB "_''
        vectors_NNS for_IN HIV_NNP immunogens_NNS ,_, including_VBG enteric_JJ bacteria_NNS ,_,
        poxviruses_NNS (_( vaccinia_NN and_CC canarypox_NN )_) ,_, small_JJ RNA_NNP viruses_NNS
        (_( e_SYM ._. g_SYM ._. poliovirus_JJ and_CC Semliki_NNP Forest_NNP virus_NN )_) ,_, Rhabdoviruses_NNP
        (_( e_SYM ._. g_SYM ._. vesicular_NN stomatitis_NNS virus_NN )_) ,_, DNA_NNP viruses_NNS (_( e_SYM ._. g_SYM ._.
        adenovirus_JJ and_CC adeno-associated_JJ viruses_NNS )_) and_CC even_RB naked_JJ DNA_NNP
        to_TO achieve_VB expression_NN in_IN living_VBG host_NN cells_NNS [_NN 2_CD 10_CD ]_NN ._.
        Dengue_NNP possesses_VBZ several_JJ advantages_NNS which_WDT favor_VBP its_PRP$
        choice_NN as_IN a_DT vector_NN for_IN HIV_NNP immunogens_NNS ._. As_IN a_DT flavivirus_JJ ,_, it_PRP
        replicates_NNS entirely_RB in_IN the_DT cytoplasm_NN through_IN RNA_NNP directed_VBD
        RNA_NNP polymerization_NN and_CC is_VBZ incapable_JJ of_IN integrating_VBG into_IN the_DT
        host_NN genome_NN ._. Flavivirus_NNP replicons_NNS can_MD replicate_VB inside_IN
        cells_NNS and_CC achieve_VB prolonged_JJ expression_NN of_IN high_JJ levels_NNS of_IN
        virally_RB encoded_JJ proteins_NNS with_IN minimal_JJ toxicity_NN [_NN 11_CD 12_CD ]_NN
        and_CC are_VBP unable_JJ to_TO recombine_NN or_CC mutate_VB to_TO produce_VB infectious_JJ
        HIV_NNP particles_NNS ._. Finally_RB ,_, by_IN eliciting_VBG an_DT immune_JJ reaction_NN
        against_IN the_DT dengue_NN non-structural_JJ proteins_NNS remaining_VBG in_IN
        replicons_NNS ,_, dengue_NN virus_NN replicons_NNS may_MD induce_VB a_DT protective_JJ
        immunity_NN against_IN dengue_NN which_WDT would_MD not_RB predispose_VB
        vaccinated_JJ individuals_NNS to_TO DHF_NNP ._. Properly_NNP administered_VBN ,_,
        dengue_NN virus_NN replicons_NNS expressing_VBG HIV_NNP epitopes_NNS might_MD thus_RB
        serve_VB as_IN dual_JJ vaccines_NNS ,_, conferring_VBG protection_NN against_IN
        dengue_NN virus_NN as_RB well_RB as_IN HIV_NNP ._.
        The_DT challenges_NNS in_IN developing_VBG a_DT safe_JJ and_CC effective_JJ HIV_NNP
        vaccine_NN are_VBP many_JJ and_CC varied_VBD ._. Choice_NN of_IN immunogen_NN is_VBZ clearly_RB
        problematic_JJ ._. Critical_JJ epitopes_NNS may_MD be_VB masked_VBN by_IN glycosyl_NN
        groups_NNS and_CC /_NN or_CC tertiary_JJ structure_NN [_NN 13_CD 14_CD 15_CD ]_NN and_CC [_NN 16_CD ]_NN
        The_DT extensive_JJ genetic_JJ variability_NN of_IN HIV_NNP complicates_VBZ
        immunogen_NN choice_NN and_CC the_DT high_JJ rate_NN of_IN mutation_NN increases_VBZ
        the_DT likelihood_NN of_IN the_DT rapid_JJ development_NN of_IN resistance_NN ._.
        Furthermore_RB ,_, the_DT method_NN of_IN immunogen_NN delivery_NN (_( e_SYM ._. g_SYM ._.
        purified_JJ subunits_NNS or_CC inactivated_JJ virus_NN vs_NNS ._. various_JJ forms_NNS of_IN
        "_'' live_VB "_'' expression_NN )_) can_MD determine_VB the_DT relative_JJ nature_NN and_CC
        extent_NN of_IN humoral_NN and_CC cell_NN mediated_JJ immunologic_JJ responses_NNS ._.
        Priming_NNP with_IN various_JJ types_NNS of_IN "_'' live_VB "_'' expression_NN followed_VBN by_IN
        boosting_VBG with_IN purified_JJ subunits_NNS is_VBZ currently_RB favored_VBN as_IN a_DT
        method_NN to_TO obtain_VB stronger_JJR immunologic_JJ responses_NNS that_IN either_DT
        method_NN alone_RB [_NN reviewed_VBN in_IN [_NN 1_CD ]_NN and_CC [_NN 2_CD ]_NN ]_NN ._. Previously_RB
        acquired_VBN immunity_NN to_TO a_DT viral_JJ vector_NN such_JJ as_IN vaccinia_NN may_MD
        influence_VB its_PRP$ efficacy_NN in_IN inducing_VBG immunity_NN against_IN
        heterologous_JJ proteins_NNS being_VBG delivered_VBN [_NN 16_CD 17_CD 18_CD 19_CD ]_NN and_CC
        it_PRP may_MD be_VB wise_JJ to_TO provide_VB physicians_NNS with_IN HIV_NNP vaccines_NNS
        based_VBN on_IN a_DT variety_NN of_IN vectors_NNS to_TO handle_VB a_DT variety_NN of_IN
        clinical_JJ situations_NNS ._.
        The_DT use_NN of_IN live_VB dengue_NN as_IN a_DT vaccine_NN or_CC as_IN a_DT vector_NN for_IN
        heterologous_JJ immunogens_NNS has_VBZ historically_RB been_VBN considered_VBN
        problematic_JJ because_IN of_IN the_DT pathologies_NNS associated_VBN with_IN
        dengue_NN infection_NN ._. Although_IN dengue_NN fever_NN (_( DF_NNP )_) is_VBZ usually_RB
        self_NN limited_JJ ,_, dengue_NN hemorrhagic_JJ fever_NN (_( DHF_NNP )_) is_VBZ
        considerably_RB debilitating_JJ and_CC frequently_RB fatal_JJ [_NN 20_CD ]_NN ._.
        However_RB ,_, DHF_NNP is_VBZ unlikely_JJ to_TO result_VB from_IN or_CC be_VB promoted_VBN by_IN
        the_DT vectors_NNS reported_VBD here_RB ._. The_DT enhanced_JJ replication_NN of_IN
        virus_NN seen_VBN in_IN dengue_NN hemorrhagic_JJ fever_NN is_VBZ generally_RB seen_VBN
        upon_IN reinfection_NN by_IN dengue_NN virus_NN of_IN a_DT serotype_NN different_JJ
        from_IN previous_JJ infections_NNS and_CC is_VBZ believed_VBN to_TO be_VB mediated_JJ by_IN
        antibodies_NNS against_IN viral_JJ structural_JJ proteins_NNS :_: so_RB called_VBN
        antibody_NN dependent_JJ enhancement_NN of_IN infection_NN ,_, or_CC ADE_NNP ._. These_DT
        cross_NN reacting_VBG antibodies_NNS actually_RB promote_VBP viral_JJ uptake_NN by_IN
        macrophages_NNS [_NN 21_CD 22_CD ]_NN ._. The_DT main_JJ challenge_NN in_IN using_VBG live_VB
        dengue_NN in_IN humans_NNS is_VBZ thus_RB avoiding_VBG the_DT development_NN of_IN
        antibody_NN dependent_JJ enhancement_NN (_( ADE_NNP )_) of_IN infection_NN by_IN
        antibodies_NNS against_IN the_DT pre-_NN M_NNP and_CC E_NNP proteins_NNS of_IN one_CD dengue_NN
        strain_NN which_WDT weakly_RB cross_NN react_VB with_IN the_DT pre-_NN M_NNP and_CC E_NNP of_IN a_DT
        second_JJ infecting_VBG dengue_NN strain_NN ._. Since_IN the_DT replicons_NNS
        reported_VBD here_RB lack_NN the_DT major_JJ viral_JJ structural_JJ protein_NN
        genes_NNS ,_, they_PRP are_VBP not_RB only_RB incapable_JJ of_IN sustaining_VBG a_DT
        spreading_VBG infection_NN but_CC also_RB are_VBP incapable_JJ of_IN eliciting_VBG
        antibodies_NNS against_IN the_DT missing_VBG structural_JJ proteins_NNS ._. They_PRP
        should_MD neither_DT induce_VB DF_NNP nor_CC promote_VB DHF_NNP ._.
        Dengue_NNP virus_NN has_VBZ a_DT typical_JJ flavivirus_JJ genome_NN structure_NN ,_,
        as_IN described_VBN in_IN Figure_NN 1_CD ._. The_DT structural_JJ proteins_NNS ,_, C_NNP ,_, pre-_NN M_NNP
        (_( M_NNP )_) and_CC E_NNP ,_, are_VBP involved_VBN in_IN packaging_NN ,_, export_NN and_CC subsequent_JJ
        entry_NN ._. The_DT non-structural_JJ proteins_NNS ,_, NS_NNP 1_CD ,_, NS_NNP 2_CD A_DT ,_, NS_NNP 2_CD B_NNP ,_, NS_NNP 3_CD ,_,
        NS_NNP 4_CD A_DT ,_, NS_NNP 4_CD B_NNP and_CC NS_NNP 5_CD include_VBP an_DT RNA-directed_NNP RNA_NNP polymerase_NN
        and_CC a_DT protease_NN function_NN involved_VBN in_IN cleaving_VBG certain_JJ
        positions_NNS of_IN the_DT long_JJ viral_JJ polyprotein_NN which_WDT contains_VBZ all_PDT
        the_DT viral_JJ genes_NNS [_NN 23_CD 24_CD ]_NN ._. The_DT four_CD serotypes_NNS of_IN dengue_NN
        virus_NN (_( "_'' 1_CD "_'' through_IN "_'' 4_CD "_'' )_) share_NN approximately_RB 60_CD %_NN -_: 74_CD %_NN amino_JJ
        acid_NN residue_NN identity_NN with_IN one_CD another_DT in_IN the_DT E_NNP gene_NN [_NN 25_CD ]_NN
        and_CC induce_VB cross-reacting_JJ antibodies_NNS [_NN 26_CD ]_NN ._.
        Two_CD strategies_NNS suggest_VBP themselves_PRP for_IN circumventing_VBG the_DT
        problem_NN of_IN ADE_NNP from_IN dengue_NN vaccination_NN ._. One_CD strategy_NN is_VBZ to_TO
        immunize_NN with_IN multiple_JJ strains_NNS of_IN dengue_NN virus_NN to_TO elicit_NN
        high_JJ affinity_NN ,_, neutralizing_VBG antibodies_NNS against_IN the_DT multiple_JJ
        dengue_NN serotypes_NNS ._. At_IN least_JJS one_CD vaccine_NN to_TO do_VB this_DT (_( using_VBG
        dengue_NN vaccine_NN candidates_NNS ,_, DEN-_NNP 1_CD PDK_NNP 13_CD ,_, DEN-_NNP 2_CD PDK_NNP 53_CD ,_, DEN-_NNP 3_CD
        PGMK_NNP 30_CD /_NN F_NN 3_CD ,_, and_CC DEN-_NNP 4_CD PDK_NNP 48_CD )_) has_VBZ been_VBN in_IN clinical_JJ trials_NNS [_NN
        27_CD 28_CD ]_NN ._. A_DT second_JJ strategy_NN is_VBZ to_TO induce_VB immunity_NN only_RB to_TO
        viral_JJ proteins_NNS other_JJ than_IN pre-_NN M_NNP and_CC E_NNP ._. Several_JJ studies_NNS have_VBP
        shown_VBN that_IN the_DT nonstructural_NN glycoprotein_NN NS_NNP 1_CD can_MD play_VB an_DT
        important_JJ role_NN in_IN protection_NN against_IN dengue_NN ._. Mice_NNS immunized_JJ
        with_IN purified_JJ dengue-_NN 2_CD NS_NNP 1_CD protein_NN injected_VBN intramuscularly_RB
        and_CC boosted_VBD after_IN 3_CD days_NNS and_CC two_CD weeks_NNS were_VBD protected_VBN from_IN
        developing_VBG lethal_JJ dengue_NN encephalitis_NNS upon_IN subsequent_JJ
        challenge_NN with_IN dengue_NN 2_CD virus_NN ._. [_NN 29_CD ]_NN ._. Similarly_RB ,_, mice_NNS
        immunized_JJ with_IN recombinant_JJ vaccinia_NN virus_NN expressing_VBG
        authentic_JJ NS_NNP 1_CD [_NN 30_CD ]_NN were_VBD protected_VBN against_IN the_DT development_NN
        of_IN dengue-_NN 4_CD virus_NN encephalitis_NNS when_WRB challenged_VBN by_IN
        intracerebral_NN injection_NN ._. Inoculation_NNP of_IN mice_NNS with_IN specific_JJ
        combinations_NNS of_IN monoclonal_NN antibodies_NNS (_( Mabs_NNP )_) directed_VBN
        against_IN dengue-_NN 2_CD NS_NNP 1_CD [_NN 31_CD ]_NN also_RB protects_VBZ against_IN lethal_JJ
        virus_NN encephalitis_NNS upon_IN intracerebral_NN dengue-_NN 2_CD challenge_NN ._.
        Other_JJ nonstructural_NN proteins_NNS are_VBP also_RB immunogenic_JJ and_CC may_MD
        participate_VB in_IN eliciting_VBG protection_NN [_NN 32_CD ]_NN ._.
        Previously_RB we_PRP have_VBP reported_VBN the_DT successful_JJ construction_NN
        of_IN several_JJ dengue_NN virus_NN replicons_NNS which_WDT replicate_VB
        intracellularly_RB without_IN the_DT pre-_NN M_NNP and_CC E_NNP proteins_NNS required_VBN
        to_TO form_VB infectious_JJ virions_NNS ,_, including_VBG one_CD replicon_NN which_WDT
        can_MD be_VB expressed_VBN from_IN transfected_JJ DNA_NNP [_NN 12_CD ]_NN ._. Towards_NNP the_DT
        goal_NN of_IN devising_VBG a_DT "_'' live_VB "_'' dual_JJ vaccine_NN based_VBN on_IN only_RB
        non-structural_JJ dengue_NN proteins_NNS and_CC heterologous_JJ HIV_NNP
        material_NN ,_, we_PRP report_VBP here_RB that_IN these_DT replicons_NNS can_MD be_VB
        harnessed_JJ to_TO express_VB heterologous_JJ genes_NNS ,_, including_VBG HIV_NNP
        gp_NN 160_CD and_CC gp_NN 120_CD ._. Upon_IN introduction_NN into_IN a_DT host_NN 's_POS cells_NNS ,_,
        these_DT sub-genomic_JJ fragments_NNS should_MD replicate_VB
        intracellularly_RB and_CC support_VB prolonged_JJ expression_NN of_IN dengue_NN
        and_CC heterologous_JJ immunogens_NNS without_IN producing_VBG the_DT deleted_VBN
        dengue_NN structural_JJ proteins_NNS and_CC without_IN forming_VBG infectious_JJ
        virions_NNS ._.
      
      
        Results_NNS
        In_IN various_JJ previous_JJ attempts_NNS to_TO express_VB heterologous_JJ
        genes_NNS in_IN full_JJ length_NN ,_, wild_JJ type_NN dengue_NN virus_NN ,_, we_PRP
        experienced_VBD a_DT very_RB poor_JJ success_NN rate_NN ,_, despite_IN attempts_NNS to_TO
        clone_NN heterologous_JJ material_NN into_IN various_JJ positions_NNS of_IN the_DT
        genome_NN (_( data_NNS not_RB shown_VBN )_) ._. Our_PRP$ first_JJ efforts_NNS to_TO determine_VB
        whether_IN or_CC not_RB heterologous_JJ material_NN could_MD be_VB readily_RB
        expressed_VBN in_IN dengue_NN replicons_NNS was_VBD to_TO clone_NN the_DT
        comparatively_RB tractable_JJ green_JJ fluorescent_NN protein_NN (_( GFP_NNP )_)
        into_IN the_DT Δpre-_NN M_NNP /_NN E_NNP replicon_NN ,_, into_IN the_DT position_NN from_IN which_WDT
        the_DT pre-_NN M_NNP and_CC E_NNP genes_NNS had_VBD been_VBN deleted_VBN (_( Figure_NN 1_LS )_) ._. GFP_NNP was_VBD
        readily_RB visualized_JJ in_IN cultures_NNS 48_CD hours_NNS post_NN transfection_NN
        with_IN Δpre-_NN M_NNP /_NN E-GFP_NNP ,_, as_IN seen_VBN in_IN Figure_NN 2_CD ._.
        Encouraged_VBN by_IN the_DT success_NN with_IN GFP_NNP ,_, we_PRP next_RB looked_VBD at_IN
        Δpre-_NN M_NNP /_NN E_NNP replicons_NNS with_IN HIV-_NNP 1_CD env_NN material_NN cloned_VBN into_IN the_DT
        position_NN of_IN the_DT deleted_VBN pre-_NN M_NNP and_CC E_NNP genes_NNS ._. We_PRP analyzed_VBD two_CD
        clones_NNS ,_, Δpre-_NN M_NNP /_NN E-_NNP gp_NN 120_CD and_CC Δpre-_NN M_NNP /_NN E-_NNP gp_NN 160_CD ,_, expressing_VBG HIV-_NNP 1_CD
        gp_NN 120_CD and_CC gp_NN 160_CD respectively_RB (_( Figure_NN 1_LS )_) ._. Expression_NNP of_IN
        genes_NNS in_IN the_DT Δpre-_NN M_NNP /_NN E-_NNP gp_NN 120_CD replicon_NN was_VBD reproducibly_RB
        visualized_JJ at_IN 48_CD -_: 50_CD hours_NNS post_NN transfection_NN (_( Figures_NNS 3_CD &_CC
        4_LS )_) ,_, at_IN a_DT level_NN of_IN approximatley_NN 1_CD %_NN of_IN the_DT cells_NNS ,_, but_CC in_IN
        many_JJ experiments_NNS ,_, the_DT corresponding_JJ cultures_NNS transfected_JJ
        with_IN the_DT gp_NN 160_CD replicon_NN ,_, Δpre-_NN M_NNP /_NN E-_NNP gp_NN 160_CD ,_, either_CC no_DT
        fluorescence_NN could_MD be_VB visualized_JJ (_( not_RB shown_VBN )_) ,_, or_CC only_RB
        fluorescent_NN cells_NNS with_IN a_DT bizarre_JJ morphology_NN (_( characterized_VBN
        by_IN debris_NN and_CC /_NN or_CC degenerative_JJ appearance_NN )_) could_MD be_VB
        visualized_JJ (_( Figure_NN 5_LS )_) ._. However_RB ,_, when_WRB we_PRP harvested_VBN cultures_NNS
        earlier_RBR ,_, at_IN 36_CD hours_NNS post_NN transfection_NN with_IN Δpre-_NN M_NNP /_NN E-_NNP gp_NN 160_CD ,_,
        intact_JJ ,_, fluorescing_VBG cells_NNS were_VBD readily_RB found_VBN ,_, though_IN the_DT
        morphology_NN still_RB appeared_VBD atypical_JJ compared_VBN to_TO either_CC that_IN
        of_IN cultures_NNS transfected_JJ with_IN wild_JJ type_NN dengue_NN virus_NN and_CC
        dengue_NN replicons_NNS [_NN 12_CD ]_NN or_CC the_DT Δpre-_NN M_NNP /_NN E-_NNP gp_NN 120_CD replicon_NN (_( see_VB
        Figure_NN 6_CD )_) ._.
        To_TO serve_VB as_IN effective_JJ vaccines_NNS ,_, it_PRP is_VBZ preferable_JJ ,_, if_IN not_RB
        necessary_JJ ,_, that_IN expression_NN systems_NNS be_VB capable_JJ of_IN expressing_VBG
        immunogens_NNS for_IN longer_RBR than_IN a_DT couple_NN of_IN days_NNS ._. Although_IN we_PRP
        knew_VBD from_IN previous_JJ experiments_NNS [_NN 12_CD ]_NN that_IN dengue_NN replicons_NNS
        could_MD survive_VB for_IN at_IN least_JJS 7_CD days_NNS in_IN culture_NN ,_, the_DT limited_JJ
        durability_NN of_IN cells_NNS transfected_JJ with_IN gp_NN 160_CD -_: expressing_VBG
        replicons_NNS raised_VBD the_DT question_NN of_IN whether_IN or_CC not_RB cells_NNS
        transfected_JJ with_IN Δpre-_NN M_NNP /_NN E-_NNP gp_NN 120_CD replicons_NNS could_MD survive_VB for_IN
        similarly_RB long_JJ times_NNS in_IN culture_NN ._. When_WRB cultures_NNS transfected_JJ
        with_IN Δpre-_NN M_NNP /_NN E-_NNP gp_NN 120_CD were_VBD trypsinized_JJ and_CC replated_JJ on_IN day_NN 7_CD
        post_NN transfection_NN and_CC then_RB analyzed_VBD on_IN day_NN 9_CD post_NN
        transfection_NN ,_, fluorescent_NN cells_NNS were_VBD readily_RB visualized_JJ
        (_( Figure_NN 7_CD )_) ._. In_IN comparison_NN to_TO cultures_NNS that_WDT were_VBD not_RB
        trypsinized_JJ on_IN day_NN 7_CD post_NN transfection_NN however_RB ,_, these_DT
        cultures_NNS had_VBD fewer_RBR intact_JJ fluorescent_NN cells_NNS and_CC more_JJR debris_NN
        (_( not_RB shown_VBN )_) ._. Although_IN this_DT suggests_VBZ that_DT gp_NN 120_CD expression_NN
        from_IN a_DT dengue_NN replicon_NN stresses_VBZ cells_NNS ,_, we_PRP did_VBD find_VB fields_NNS
        with_IN adjacent_JJ ,_, gp_NN 120_CD positive_JJ cells_NNS ,_, suggesting_VBG that_IN at_IN
        least_JJS one_CD cell_NN division_NN between_IN day_NN 7_CD and_CC day_NN 9_CD had_VBD
        occurred_VBN in_IN a_DT cell_NN successfully_RB transfected_JJ with_IN
        Δpre-_NN M_NNP /_NN E-_NNP gp_NN 120_CD (_( Figure_NN 7_CD ,_, right_JJ panel_NN )_) ._. A_DT 9_CD days_NNS of_IN culture_NN
        post_NN transfection_NN with_IN Δpre-_NN M_NNP /_NN E-_NNP gp_NN 120_CD ,_, only_RB about_IN 0_CD ._. 1_CD %_NN of_IN
        the_DT cells_NNS or_CC less_JJR were_VBD positive_JJ (_( not_RB shown_VBN )_) ,_, which_WDT
        represents_VBZ a_DT considerable_JJ decrease_NN from_IN 48_CD hours_NNS post_NN
        transfection_NN ._.
        In_IN the_DT experiments_NNS described_VBD above_IN and_CC in_IN Figures_NNS
        3_CD through_IN 7_CD ,_, expression_NN of_IN dengue_NN replicons_NNS with_IN
        heterologous_JJ material_NN from_IN HIV_NNP was_VBD followed_VBN either_CC using_VBG
        anti-_NN HIV_NNP sera_NN or_CC anti-dengue_JJ sera_NN ,_, depending_VBG on_IN the_DT
        experiment_NN ._. To_TO demonstrate_VB that_IN the_DT same_JJ cells_NNS were_VBD
        expressing_VBG both_DT dengue_NN proteins_NNS and_CC HIV_NNP proteins_NNS ,_, we_PRP used_VBD a_DT
        double_JJ label_NN technique_NN ,_, with_IN FITC_NNP detecting_VBG HIV_NNP proteins_NNS
        and_CC rhodamine_NN detecting_VBG dengue_NN proteins_NNS ._. Figure_NN
        8_CD demonstrates_VBZ the_DT concordance_NN of_IN dengue_NN virus_NN protein_NN and_CC
        gp_NN 120_CD expression_NN in_IN cultures_NNS 4_CD days_NNS post_NN transfection_NN with_IN
        Δpre-_NN M_NNP /_NN E-_NNP gp_NN 120_CD ,_, (_( Figure_NN 8_CD )_) ._. The_DT more_RBR extensive_JJ background_NN
        of_IN auto_NN fluorescence_NN encountered_VBD when_WRB visualizing_VBG the_DT
        rhodamine_NN fluorescence_NN makes_VBZ low_JJ levels_NNS of_IN specific_JJ
        rhodamine_NN fluorescence_NN more_RBR difficult_JJ to_TO discern_VB ,_, but_CC
        clearly_RB all_DT intact_JJ cells_NNS positive_JJ for_IN HIV_NNP are_VBP also_RB positive_JJ
        for_IN dengue_NN proteins_NNS ._. The_DT rhodamine-positive_JJ spot_NN in_IN the_DT
        lower_JJR left_VBN of_IN the_DT panel_NN is_VBZ cellular_JJ debris_NN and_CC is_VBZ also_RB
        positive_JJ for_IN dengue_NN proteins_NNS ,_, but_CC the_DT FITC_NNP fluorescence_NN was_VBD
        not_RB well_RB reproduced_VBD by_IN digital_JJ photography_NN ,_, though_IN it_PRP still_RB
        may_MD be_VB visualized_JJ on_IN certain_JJ monitor_NN /_NN computer_NN combinations_NNS ._.
        Similar_JJ results_NNS were_VBD obtained_VBN at_IN 7_CD days_NNS post_NN transfection_NN
        (_( Figure_NN 9_CD )_) ._.
      
      
        Discussion_NNP
        Our_PRP$ finding_VBG that_DT dengue_NN virus_NN replicons_NNS can_MD express_VB
        heterologous_JJ genes_NNS ,_, including_VBG HIV_NNP envelop_NN ,_, for_IN prolonged_JJ
        periods_NNS of_IN time_NN in_IN cell_NN culture_NN without_IN selection_NN
        represents_VBZ a_DT significant_JJ step_NN in_IN developing_VBG a_DT new_JJ vector_NN
        system_NN potentially_RB capable_JJ of_IN delivering_VBG immunogens_NNS to_TO any_DT
        host_NN in_IN whose_WP$ cells_NNS the_DT dengue_NN replicons_NNS can_MD replicate_VB ._.
        Flavivirus_NNP replicons_NNS have_VBP previously_RB been_VBN demonstrated_VBN to_TO
        express_VB heterologous_JJ genes_NNS for_IN up_IN to_TO 41_CD days_NNS in_IN tissue_NN
        culture_NN in_IN Kunjin_NNP [_NN 11_CD ]_NN ._. However_RB ,_, these_DT experiments_NNS were_VBD
        done_VBN in_IN the_DT presence_NN of_IN selection_NN for_IN the_DT heterologous_JJ
        genes_NNS cloned_VBN into_IN the_DT replicons_NNS ._. We_PRP have_VBP demonstrated_VBN
        heterologous_JJ gene_NN expression_NN in_IN the_DT absence_NN of_IN selection_NN
        for_IN up_IN to_TO at_IN least_JJS 9_CD days_NNS post_NN transfection_NN with_IN chimeric_JJ
        dengue_NN replicons_NNS ._. Although_IN we_PRP have_VBP formally_RB demonstrated_VBN
        expression_NN ,_, not_RB replication_NN ,_, our_PRP$ previous_JJ demonstration_NN of_IN
        the_DT replication_NN [_NN 12_CD ]_NN of_IN dengue_NN replicons_NNS lacking_VBG
        heterologous_JJ material_NN suggests_VBZ that_IN the_DT replicons_NNS described_VBD
        here_RB ,_, which_WDT contain_VBP heterologous_JJ material_NN ,_, are_VBP indeed_RB
        replicating_VBG ._. Evidence_NN that_IN cells_NNS continue_VBP to_TO replicate_VB and_CC
        express_VB replicon_NN proteins_NNS in_IN both_DT daughter_NN cells_NNS after_IN
        transfection_NN with_IN these_DT chimeric_JJ replicons_NNS further_JJ supports_VBZ
        the_DT implication_NN of_IN chimeric_JJ replicon_NN replication_NN ._. Ideally_RB ,_,
        to_TO serve_VB as_IN dual_JJ vaccines_NNS against_IN dengue_NN as_RB well_RB as_IN against_IN
        other_JJ pathogens_NNS ,_, the_DT replicons_NNS should_MD express_VB the_DT dengue_NN
        NS_NNP 1_CD protein_NN [_NN 29_CD 30_CD 31_CD 32_CD ]_NN ._. So_RB far_RB ,_, attempts_VBZ to_TO visualize_VB
        NS_NNP 1_CD production_NN by_IN Western_JJ blots_NNS have_VBP failed_VBN ,_, presumably_RB
        because_IN of_IN the_DT low_JJ transfection_NN efficiencies_NNS ._. However_RB ,_, we_PRP
        have_VBP previously_RB argued_VBN that_IN the_DT replication_NN of_IN dengue_NN
        replicons_NNS could_MD not_RB take_VB place_NN in_IN the_DT absence_NN of_IN the_DT
        essential_JJ non-structural_JJ gene_NN ,_, NS_NNP 1_CD ,_, which_WDT implies_VBZ that_IN NS_NNP 1_CD
        is_VBZ being_VBG made_VBN ._. The_DT frequencies_NNS and_CC fluorescence_NN intensities_NNS
        of_IN replicon_NN positive_JJ cells_NNS seen_VBN in_IN the_DT experiments_NNS reported_VBD
        here_RB are_VBP comparable_JJ to_TO those_DT seen_VBN for_IN dengue_NN replicons_NNS
        lacking_VBG heterologous_JJ material_NN [_NN 12_CD ]_NN ,_, suggesting_VBG that_DT
        replication_NN of_IN the_DT Δpre-_NN M_NNP /_NN E_NNP replicons_NNS containing_VBG
        heterologous_JJ material_NN is_VBZ occurring_VBG as_RB well_RB ._. The_DT finding_NN of_IN
        at_IN least_JJS one_CD closely_RB apposed_JJ pair_NN of_IN cells_NNS expressing_VBG high_JJ
        levels_NNS of_IN replicon_NN proteins_NNS on_IN day_NN 9_CD post_NN transfection_NN ,_, two_CD
        days_NNS after_IN trypsinization_NN and_CC replating_VBG (_( Figure_NN 7_CD ,_, right_JJ
        panel_NN )_) ,_, not_RB only_RB implies_VBZ replicon_NN replication_NN ,_, but_CC also_RB
        implies_VBZ the_DT expression_NN of_IN NS-_NNP 1_CD protein_NN as_RB well_RB ._. The_DT
        definitive_JJ demonstration_NN of_IN effective_JJ NS-_NNP 1_CD production_NN will_MD
        have_VB to_TO await_VB studies_NNS of_IN the_DT immune_JJ response_NN in_IN animals_NNS
        immunized_JJ with_IN these_DT replicons_NNS ._.
        Choice_NN of_IN immunogen_NN remains_VBZ problematic_JJ for_IN these_DT
        vectors_NNS ._. Clearly_RB ,_, HIV-_NNP 1_CD gp_NN 160_CD is_VBZ too_RB toxic_JJ for_IN prolonged_JJ
        expression_NN ._. Even_RB the_DT gp_NN 120_CD -_: expressing_VBG replicon_NN seems_VBZ mildly_RB
        toxic_JJ in_IN that_IN the_DT frequency_NN of_IN gp_NN 120_CD positive_JJ cells_NNS
        declines_NNS with_IN time_NN in_IN culture_NN post_NN transfection_NN with_IN
        Δpre-_NN M_NNP /_NN E-_NNP gp_NN 120_CD (_( not_RB shown_VBN )_) ._. However_RB ,_, as_IN noted_VBN above_IN ,_, we_PRP
        have_VBP seen_VBN at_IN least_JJS one_CD instance_NN of_IN putative_JJ cellular_JJ
        division_NN at_IN least_JJS 7_CD days_NNS after_IN being_VBG successfully_RB
        transfected_JJ by_IN Δpre-_NN M_NNP /_NN E-_NNP gp_NN 120_CD (_( Figure_NN 7_CD ,_, right_JJ panel_NN )_) ._.
        Experiments_NNS are_VBP now_RB in_IN progress_NN to_TO determine_VB the_DT
        feasibility_NN of_IN long_JJ term_NN expression_NN of_IN other_JJ HIV-_NNP 1_CD
        immunogens_NNS ,_, including_VBG gag_NN and_CC tat_NN ._.
      
      
        Conclusion_NNP
        Demonstration_NNP of_IN long_JJ term_NN protein_NN expression_NN by_IN a_DT
        gp_NN 120_CD -_: expressing_VBG replicon_NN alone_RB ,_, of_IN course_NN ,_, does_VBZ not_RB
        demonstrate_VB that_IN the_DT chimeric_JJ dengue_NN replicons_NNS constitute_VBP
        an_DT effective_JJ vaccine_NN ._. However_RB ,_, at_IN the_DT very_RB least_JJS they_PRP add_VBP
        to_TO the_DT potential_JJ armamentarium_NN available_JJ to_TO the_DT
        vaccinologist_NN ._. It_PRP is_VBZ highly_RB likely_JJ that_IN a_DT successful_JJ HIV_NNP
        vaccination_NN protocol_NN will_MD involve_VB multiple_JJ immunogens_NNS and_CC
        delivery_NN protocols_NNS ._. For_IN instance_NN ,_, mice_NNS immunized_JJ with_IN
        attenuated_JJ Friend_NNP leukemia_NN virus_NN (_( FLV_NNP )_) develop_VB an_DT immune_JJ
        response_NN whose_WP$ efficacy_NN is_VBZ dependent_JJ on_IN the_DT additive_JJ
        effects_NNS of_IN at_IN least_JJS three_CD separable_JJ spleen_NN cell_NN populations_NNS
        [_NN 33_CD ]_NN ._. By_IN analogy_NN ,_, it_PRP may_MD be_VB necessary_JJ to_TO devise_VB multiple_JJ
        strategies_NNS to_TO obtain_VB a_DT similarly_RB complex_JJ and_CC effective_JJ
        immune_JJ response_NN in_IN humans_NNS against_IN HIV_NNP ._. In_IN animal_NN models_NNS of_IN
        HIV_NNP ,_, different_JJ immunogens_NNS and_CC modes_NNS of_IN immunization_NN can_MD
        induce_VB different_JJ modes_NNS of_IN protection_NN with_IN varying_VBG degrees_NNS
        of_IN effectiveness_NN [_NN 34_CD 35_CD 36_CD 37_CD 38_CD 39_CD 40_CD ]_NN Harnessing_NNP
        multiple_JJ immune_JJ responses_NNS may_MD be_VB the_DT answer_NN to_TO designing_VBG an_DT
        effective_JJ HIV_NNP vaccine_NN [_NN 1_CD ]_NN and_CC the_DT availability_NN of_IN
        multiple_JJ vectors_NNS may_MD facilitate_VB the_DT harnessing_VBG of_IN multiple_JJ
        responses_NNS ._.
        Much_JJ work_NN obviously_RB remains_VBZ to_TO be_VB done_VBN to_TO develop_VB dengue_NN
        replicons_NNS as_IN effective_JJ vectors_NNS for_IN HIV_NNP immunogens_NNS ._. More_JJR
        work_NN needs_VBZ to_TO be_VB done_VBN on_IN determining_VBG the_DT ability_NN of_IN dengue_NN
        replicons_NNS to_TO express_VB other_JJ potential_JJ immunogens_NNS ,_, including_VBG
        HIV-_NNP 1_CD gag_NN ,_, tat_NN (_( reviewed_VBN in_IN 41_CD )_) and_CC env_NN genes_NNS with_IN deleted_VBN
        hypervariable_JJ regions_NNS [_NN see_VB [_NN 42_CD ]_NN ]_NN ._. Animal_NNP studies_NNS in_IN our_PRP$
        lab_NN are_VBP currently_RB being_VBG initiated_VBN to_TO determine_VB the_DT nature_NN
        of_IN the_DT immune_JJ response_NN such_JJ vectors_NNS can_MD induce_VB in_IN mice_NNS and_CC
        these_DT studies_NNS will_MD presumably_RB need_VB to_TO be_VB extended_VBN to_TO
        primates_NNS ._. Finally_RB ,_, effective_JJ delivery_NN systems_NNS will_MD need_VB to_TO
        be_VB devised_VBN ._. Although_IN our_PRP$ successful_JJ development_NN of_IN a_DT
        plasmid_NN which_WDT can_MD express_VB a_DT dengue_NN replicon_NN from_IN
        transfected_JJ DNA_NNP facilitates_NNS delivery_NN by_IN DNA_NNP vaccination_NN [_NN
        12_CD ]_NN ,_, the_DT development_NN of_IN packaging_VBG cell_NN lines_NNS which_WDT can_MD
        package_VB these_DT replicons_NNS into_IN virions_NNS would_MD be_VB a_DT major_JJ step_NN
        forward_RB towards_IN a_DT vaccine_NN which_WDT could_MD be_VB conveniently_RB
        administered_VBN in_IN typical_JJ clinical_JJ situations_NNS ._. Experiments_NNS
        are_VBP currently_RB underway_NN in_IN our_PRP$ laboratory_NN to_TO develop_VB such_JJ
        packaging_VBG cell_NN lines_NNS ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Culturing_NNP of_IN dengue_NN Virus_NNP
          Dengue_NNP virus_NN strains_NNS DEN_NNP 1_CD /_NN WP_NNP and_CC DEN_NNP 2_CD /_NN NGC_NNP ,_, kindly_RB
          provided_VBN by_IN Dr_NNP ._. Lewis_NNP Markoff_NNP ,_, [_NN 43_CD 44_CD ]_NN were_VBD passaged_JJ in_IN
          monkey_NN LLC-MK_NNP 2_CD cells_NNS at_IN 37_CD °_NN C_NNP in_IN a_DT humidified_JJ incubator_NN
          under_IN 5_CD %_NN CO_NNP 2_CD ,_, using_VBG Medium_NNP 199_CD plus_CC 10_CD %_NN fetal_JJ bovine_JJ
          serum_NN (_( FBS_NNP )_) and_CC 50_CD ug_NN of_IN Gentamicin_NNP per_IN ml_NN ._. The_DT cells_NNS
          were_VBD trypsinized_JJ a_DT day_NN before_IN virus_NN infection_NN and_CC plated_JJ
          to_TO reach_VB approximately_RB 80_CD %_NN confluence_NN on_IN the_DT day_NN of_IN
          infection_NN ._. Infections_NNP were_VBD typically_RB at_IN an_DT MOI_NNP of_IN 0_CD ._. 01_CD
          PFU_NNP /_NN cell_NN in_IN Medium_NNP 199_CD plus_CC 2_CD %_NN FBS_NNP ._.
        
        
          In_IN vitro_NN mutagenesis_NNS
          Heterologous_NNP genes_NNS were_VBD cloned_VBN into_IN the_DT previously_RB
          described_VBN Δpre-_NN M_NNP /_NN E_NNP replicon_NN [_NN 12_CD ]_NN ,_, into_IN the_DT position_NN
          previously_RB occupied_VBN by_IN the_DT pre-_NN M_NNP /_NN E_NNP genes_NNS ._. DNA_NN fragments_NNS
          used_VBN for_IN desired_VBN regions_NNS of_IN heterologous_JJ genes_NNS (_( see_VB
          Figure_NN 1_LS )_) were_VBD synthesized_JJ by_IN polymerase_NN chain_NN reaction_NN
          (_( PCR_NNP )_) from_IN short_JJ overlapping_VBG primers_NNS ._. For_IN the_DT Green_NNP
          Fluorescent_NNP Protein_NNP (_( GFP_NNP )_) gene_NN ,_, the_DT 5_CD '_POS primer_NN was_VBD
          5_CD '_POS CGAAAAAAGGCGAGAAATACGCCTTTCAATATGCTGAAACGCGAGAGAATGGTGAGCAAGGGCGAGGAGCTG_NNP 3_CD '_POS
          and_CC the_DT 3_CD '_POS primer_NN was_VBD
          5_CD '_POS AAGGTCAAAATTCAACAGCTGCTTGTACAGCTCGTCCATGCC_NNP 3_CD '_'' ._. For_IN HIV-_NNP 1_CD
          gp_NN 120_CD gene_NN ,_, the_DT 5_CD '_POS primer_NN was_VBD
          5_CD '_POS ATCATTATGCTGAATCCAACAGTGATGGCGTTCCATTTACCACACGTAACATGAGAGTGATGGGGATCAGGAAG_NNP 3_CD '_POS
          and_CC the_DT 3_CD '_POS primer_NN was_VBD
          5_CD '_POS AAGGTCAAAATTCAACAGCTGGGTGGGTGCTAATCCTAATGGTTC_NNP 3_CD '_'' ._. GFP_NNP
          and_CC HIV-_NNP 1_CD gp_NN 120_CD were_VBD fused_JJ with_IN FMDV_NNP /_NN 2_CD A_DT self_NN cleaving_VBG
          protein_NN sequence_NN to_TO replace_VB natural_JJ cleavage_NN sites_NNS in_IN the_DT
          dengue_NN polyprotein_NN ._. These_DT sites_NNS seem_VBP to_TO loose_VB their_PRP$
          activity_NN when_WRB juxtaposed_JJ with_IN heterologous_JJ material_NN (_( data_NNS
          not_RB shown_VBN )_) ._. PCR_NNP was_VBD used_VBN to_TO amplify_VB DNA_NNP coding_VBG for_IN the_DT
          FMDV_NNP /_NN 2_CD A_DT self_NN cleaving_VBG protein_NN The_DT 5_CD '_POS primer_NN was_VBD
          5_CD '_POS CAGCTGTTGAATTTTGACCTTCTTAAGCTTGCGGGAGACGTCGAGTCCAACCCTGGCCCC_NNP 3_CD '_POS
          and_CC the_DT 3_CD '_POS primer_NN was_VBD
          5_CD '_POS ATACAGCGTCACGACTCCCACCAATACTAGTGACACAGACAGTGAGGTGCTGGGGCCAGGGTTGGACTCGAC_NNP ._.
          Dengue-_NNP 2_CD virus_NN cDNA_NN cloned_VBN in_IN the_DT yeast_NN shuttle_NN vector_NN
          pRS_NN 424_CD ,_, linearized_JJ by_IN excision_NN of_IN a_DT short_JJ Bam_UH H_NNP 1_CD fragment_NN
          was_VBD transfected_JJ into_IN competent_JJ [_NN 45_CD ]_NN S_NNP ._. cerevisiae_NN
          YPH_NNP 857_CD (_( kindly_RB provided_VBN by_IN Barry_NNP Falgout_NNP ,_, (_( CBER_NNP /_NN FDA_NNP )_) ,_,
          along_IN with_IN the_DT appropriate_JJ PCR_NNP fragment_NN spanning_VBG the_DT
          desired_VBN deletion_NN ._. Yeast_NN colonies_NNS which_WDT grew_VBD on_IN tryptophan_NN
          minus_CC plates_NNS represented_VBD vectors_NNS which_WDT had_VBD recircularized_JJ
          by_IN homologous_RB recombination_NN with_IN these_DT PCR_NNP fragments_NNS [_NN 35_CD
          ]_NN ._. DNA_NNP from_IN these_DT colonies_NNS was_VBD transformed_VBN into_IN E_NNP ._. coli_NNS
          STBL_NNP 2_CD cells_NNS (_( Life_NNP Technologies_NNPS ,_, Inc_NNP ._. )_) to_TO make_VB sufficient_JJ
          quantities_NNS of_IN dengue_NN recombinant_JJ ,_, genomic-length_JJ DNAs_NNP for_IN
          characterization_NN and_CC analysis_NN ._.
        
        
          Expression_NNP of_IN virus_NN &_CC replicons_NNS in_IN cells_NNS
          The_DT full_JJ length_NN virus_NN and_CC replicon_NN cDNA_NN plasmids_NNS
          isolated_VBN from_IN STBL_NNP 2_CD cells_NNS were_VBD linearized_JJ with_IN Sac_NNP I_PRP ,_,
          purified_JJ by_IN Qiagen_NNP chromatography_NN ,_, and_CC eluted_JJ by_IN
          RNAase-free_NNP water_NN in_IN preparation_NN for_IN transcription_NN ._. The_DT
          transcription_NN reaction_NN mixtures_NNS contained_VBD lug_NN of_IN
          linearized_JJ DNA_NNP ;_: 0_CD ._. 5_CD mM_NN (_( each_DT )_) ATP_NNP ,_, CTP_NNP ,_, and_CC UTP_NNP ;_: 0_CD ._. 1_CD mM_NN
          GTP_NNP ;_: 0_CD ._. 5_CD mM_NN cap_NN analog_NN (_( NEBL_NNP )_) ;_: 10_CD mM_NN DTT_NNP ;_: 40_CD U_NNP of_IN Rnasin_NNP
          (_( Promega_NNP )_) ;_: 30_CD U_NNP of_IN SP_NNP 6_CD RNA_NNP polymerase_NN ;_: and_CC 1_CD ×_NN SP_NNP 6_CD RNA_NNP
          polymerase_NN buffer_NN (_( Promega_NNP )_) in_IN a_DT volume_NN of_IN 30_CD ul_NN ._. The_DT
          reaction_NN mixtures_NNS were_VBD incubated_JJ at_IN 400_CD °_NN C_NNP for_IN 2_CD hr_NN ._.
          Aliquots_NNP (_( 12_CD ._. 5_LS ul_NN )_) of_IN the_DT reaction_NN mixtures_NNS ,_, containing_VBG
          full_JJ length_NN viral_JJ RNA_NNP ,_, were_VBD used_VBN to_TO transfect_NN
          approximately_RB 2_CD ×_NN 106_CD Monkey_NNP LLC-MK_NNP 2_CD cells_NNS in_IN
          phosphate-buffered_JJ saline_NN (_( PBS_NNP )_) by_IN electroporation_NN in_IN a_DT
          0_CD ._. 4_CD cm_NN gap_NN electroporation_NN cuvette_NN ._. Each_DT cuvette_NN was_VBD
          pulsed_JJ at_IN 200_CD V_NNP ,_, 950_CD uF_NN using_VBG a_DT BioRad_NNP Genepuls_NNP
          electroporator_NN ._. The_DT cells_NNS were_VBD then_RB resuspended_JJ in_IN growth_NN
          medium_NN and_CC plated_JJ on_IN the_DT appropriate_JJ tissue_NN culture_NN
          dish_NN ._.
          After_IN electroporation_NN ,_, cells_NNS were_VBD either_CC plated_JJ
          directly_RB on_IN multiwell_NN plates_NNS for_IN harvest_NN at_IN short_JJ time_NN
          periods_NNS (_( typically_RB 4_CD days_NNS or_CC less_JJR )_) or_CC on_IN tissue_NN culture_NN
          dishes_NNS for_IN trypsinization_NN and_CC seeding_VBG onto_IN multiwell_NN
          plates_NNS one_CD or_CC two_CD days_NNS before_IN final_JJ harvest_NN for_IN longer_JJR
          time_NN periods_NNS ._.
        
        
          Immuno-histochemical_NNP methods_NNS
          For_IN immunofluorescent_NN detection_NN of_IN dengue-specific_JJ
          proteins_NNS ,_, cells_NNS growing_VBG on_IN chamber_NN slides_NNS were_VBD rinsed_JJ in_IN
          room-temperature_JJ PBS_NNP and_CC then_RB fixed_VBN in_IN cold_JJ acetone_NN for_IN
          10_CD min_NN at_IN -_: 20_CD °_NN C_NNP ._. After_IN being_VBG air_NN dried_VBD ,_, each_DT chamber_NN was_VBD
          covered_VBN with_IN 50_CD ul_NN of_IN a_DT 1_CD :_: 50_CD dilution_NN of_IN DEN_NNP 2_CD -_: specific_JJ
          hyperimmune_NN mouse_NN ascitic_JJ fluid_JJ (_( HMAF_NNP ,_, American_NNP Type_NNP
          Culture_NNP Collection_NNP )_) in_IN PBS_NNP plus_CC 2_CD %_NN normal_JJ goat_NN serum_NN and_CC
          incubated_JJ at_IN room_NN temperature_NN for_IN 1_CD h_NN in_IN a_DT humidified_JJ
          atmosphere_NN and_CC then_RB rinsed_JJ twice_RB in_IN PBS_NNP ._. After_IN washing_VBG ,_,
          cells_NNS were_VBD subsequently_RB incubated_JJ with_IN a_DT 1_CD :_: 100_CD dilution_NN
          of_IN fluorescein_NN isothiocyanate-labeld_JJ goat_NN anti-mouse_JJ
          antibodies_NNS (_( Kirkegaard_NNP and_CC Perry_NNP Laboratory_NNP )_) and_CC rinsed_JJ
          twice_RB in_IN PBS_NNP ._. For_IN detection_NN of_IN HIV-specific_NNP proteins_NNS ,_, the_DT
          same_JJ protocol_NN was_VBD used_VBN except_IN that_DT cells_NNS were_VBD initially_RB
          incubated_JJ with_IN human_JJ HIV-_NNP 1_CD serum_NN from_IN Waldheim_NNP
          Pharmazeutika_NNP Ges_NNP ._. m_NN ._. b_SYM ._. H_NNP ._. Neufeld-_NNP Vienna_NNP ,_, Austria_NNP and_CC then_RB
          subsequently_RB incubated_JJ with_IN fluorescent-labeled_JJ goat_NN
          anti-human_JJ antibody_NN ._. Cells_NNP in_IN some_DT ,_, but_CC not_RB all_DT
          experiments_NNS were_VBD counterstained_JJ with_IN 0_CD ._. 02_CD %_NN Evans_NNP
          Blue_NNP ._.
          For_IN dual_JJ labeling_VBG ,_, the_DT first_JJ antibodies_NNS were_VBD a_DT 1_CD :_: 50_CD
          dilution_NN of_IN dengue_NN type_NN 2_CD specific_JJ hyperimmune_NN mouse_NN
          ascitic_JJ fluid_JJ (_( HMAF_NNP ,_, American_JJ type_NN culture_NN collection_NN )_)
          and_CC a_DT 1_CD :_: 100_CD dilution_NN of_IN human_JJ HIV_NNP positive_JJ serum_NN in_IN PBS_NNP
          plus_CC 2_CD %_NN normal_JJ goat_NN serum_NN ._. The_DT second_JJ antibodies_NNS were_VBD a_DT
          1_CD :_: 100_CD dilution_NN of_IN FITC-labeled_NNP goat_NN anti-human_JJ antibodies_NNS
          (_( Waldeim_NNP Pharmazeutika_NNP )_) and_CC a_DT 1_CD :_: 50_CD dilution_NN of_IN goat_NN
          anti-mouse_JJ IgG-L-Rhodamine_NNP (_( Boehringer_NNP Mannheim_NNP
          Biochemicals_NNP )_) ._.
        
      
    
  
